tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Talaris Therapeutics to suspend further guidance on status of programs

As the Company assesses strategic alternatives, it will suspend further guidance on the status of its programs. As of December 31, 2022, the Company’s cash, cash equivalents and short- and long-term marketable securities were approximately $181.3 million.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Disclaimer & DisclosureReport an Issue

1